Exiqon

The Copenhagen-based company continues its relationship with Aarhus University Hospital by licensing the prostate cancer biomarkers.

The Danish firm's research business grew 24 percent and its North American revenues grew 52 percent.

The firm said the first quarter was the best quarter in its history and reiterated its full-year guidance for 2015.

Transgenomic has gained the rights to use Exiqon's locked nucleic acid oligonucleotides for several platforms, including NGS and ICE COLD-PCR.

The Danish miRNA firm reported record sales of products and services, and narrowed its net loss for 2014.

Exiqon announces an exclusive agreement with Aarhus University Hospital to license prostate cancer biomarkers discovered and validated by the hospital.

NEW YORK (GenomeWeb) – Exiqon today reported that its third quarter revenues increased 17 percent year over year to DKK 34.8 million ($5.9 million) from DKK 29.8 million.

NEW YORK (GenomeWeb) – Danish miRNA biomarker firm Exiqon reported today an 8 percent decrease year over year in its second quarter revenues.

NEW YORK (GenomeWeb) – An international team of academic and industry researchers this week published the results of a comparison of commercially available platforms for microRNA expression analysis, finding that each has its own strengths and shortcomings that should be considered before selecti

Mo Bio Laboratories this week launched the BiOstic FFPE Tissue RNA Isolation Kit.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.